Merck
Dow Rises Despite Europe's Woes
4:28PM 1/17/2012
Economy, Investing, JP Morgan Chase, Citigroup, Merck, Market News
On Friday, it looked like this week would be ugly. Standard & Poor's had just downgraded the credit ratings of France and several other E.U. countries, the latest domino to fall in Europe's slow-motion economic train wreck. But at least in the U.S., the stock market has shrugged off that news.
A Simple Strategy to Boost Your Returns
1:35PM 10/18/2011
By John Rosevear, The Motley Fool
Pfizer, Bristol-Myers Squibb, Verizon, McDonald's, Merck, Investing Basics, Chevron
Options: It's a word that makes you shiver with fear or salivate at opportunity. In fact, there's one options strategy that's almost certain to add some extra money to your portfolio over time, without adding lots of risk. It's the technique known as writing covered calls, and it's perfect for times like this.
The New Chicken and Egg Conundrum: Jobs or Profits?
11:00AM 8/11/2011
By Travis Hoium, The Motley Fool
Google , Pfizer, Campbell Soup Company, Merck, General Motors, Cisco Systems, Whole Foods
Lots of companies are laying off workers, trying to cut costs and improve their profit margins. But how should investors view the news of job cuts at a company? As a sign of deep trouble and worse to come, or as proof of committed management and better times ahead? Here's how to read the pink slips.
Three Ways to Overcome Your Retirement Doubts
2:00PM 4/27/2011
Retirement, Economy, Investing, AT&T, Stock Picks, Merck, Market News, Investment
With the majority of workers convinced that they will not receive Social Security and will be unable to retire, the market may be the best option for the future. Here's some ways to make stocks work for your retirement.
Is Celgene the Perfect Stock?
2:00PM 4/06/2011
Company News, Technology, Economy, Investing, Health Care, Genzyme Corporation , Pfizer, Merck, Market News, Investment
With an attractive balance sheet, healthy revenue growth and a solid return on equity, biotech company Celgene looks like a promising stock buy.
The Millionaire Class: Most New U.S. Senators are Rich
6:30PM 3/09/2011
Approximately 60% of first-year U.S. senators and 40% of House of Representatives freshmen are worth at least $1 million, according to the Center for Responsive Politics. That makes them far richer than most of the Americans they represent: Just 1% of the country's population has reached the $1 million mark.
The 10 Biggest-Selling Drugs That Are About to Lose Their Patent
8:00AM 2/27/2011
Company News, Investing, Health Care, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Merck, Eli Lilly, Astrazeneca
The pharmaceutical industry is ready to fall off a cliff -- a "patent cliff." Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from drugmakers' bottom lines.
Pharmaceuticals Look Beyond Medications to Smartphone Apps
11:10AM 2/16/2011
Health Care, Pfizer, Qualcomm, Apple, Sanofi Aventis, Merck, GlaxoSmithKline, Novartis, Cisco Systems
Pharmaceutical companies looking for fresh sources of profit are increasingly investing in a range of health care innovations that aren't drugs at all, from smartphone apps and educational websites to social media platforms and wireless devices, reports Ernst & Young.
Inside Wall Street: Two Good Reasons for Clinical Data Shares to Soar Again
8:00AM 2/14/2011
Company News, Columns, Investing, Health Care, Pfizer, Stock Picks, Merck, GlaxoSmithKline, Eli Lilly
From October 2010 to February 2011, biotech Clinical Data's stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up -- and making it likely to perhaps double again -- is speculation that a Big Pharma will buy Clinical Data.
Merck Posts $531 Million Loss in Fourth Quarter
7:48AM 2/03/2011
Drugmaker Merck & Co. (MRK) said Thursday it lost $531 million in the fourth quarter due to nearly $4 billion charges, including writeoffs and restructuring costs from its acquisition of Schering-Plough Corp. in 2009.
Almost half of the charges were to account for diminished prospects for...
Most Popular Stories
Why Your 2012 Tax Bill May Jump By $8,000
Savings Experiment: Tissues vs. Toilet Paper
Why the U.S. Should Get Rid of the $1 Bill
7 Startling Numbers We Now Know About Facebook
Wrecks to Riches: Hunting Sunken Treasures from Cape Cod to the Costa ConcordiaDailyFinance Wire
Newswire
- Greek austerity talks stall on pension cuts
- Stocks rally from early losses to close higher
- Sprint posts deeper 4Q loss on iPhone costs
- For college bound, a look at financial aid...
- Lawsuit seeks to block Google's privacy changes
- Groupon reports 4Q loss, higher revenue
- Cisco beats estimates with 2Q earnings, sales
- Builders group sees pickup in housing this year
- Government assistance expands
- Bob Rodriguez: The best advice I ever got
- Adventure travel bargains
- University of Charleston: How we cut tuition...
- Investing for retirement when you're just...
- Get more from a second doctor's opinion
- The Romney kids' $100 million trust fund
- Finally, a foreclosure settlement (Maybe)
- Nearly 200,000 Sign Petition Against Apple Supplier Use
- Facebook Already Amends Its IPO Filing Paperwork (FB)
- Cisco Boosts Earnings & Dividend (CSCO)
- Groupon Headline Loss Trumps Revenue Beat (GRPN)
- 24/7 Wall St. Closing Bell (YUM, DMD, NLY, MS, UBS, AGU, CVS, RL, RAI, TWX, DIS, WYN, BWLD, CSCO, CZR, FFN, TNK, AKAM, NURO)
- Top Earnings Previews For Thursday (ATVI, BG, CBOE, DNKN, EXPE, LNKD, MPEL, NUAN, PEP, PBR, PM, RSG, SIRI, SON, TDC)
- 360-Degree Cisco Earnings Preview (CSCO, ORCL, JNPR, ALU)
- Mid-day Movers (CZR, SANW, CALX, POWL, NURO)
Follow Us
